Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
ASO International, Inc. (9340.T)
Tokyo, JP
Established in 1982 and headquartered in Tokyo, Japan, ASO International, Inc. is a key player in the orthodontics sector, providing a comprehensive array of products and services. The company develops and supplies advanced systems for teeth alignment, including SYMPHONY, an indirect bonding solution; HARMONY, focused on lingual (tongue-side) correction; and CHANGE, designed for full-jaw orthodontic treatment. ASO also leverages cutting-edge additive manufacturing technology with its SATT SYSTEMS, which employs a novel LCD method 3D printer, and HEYGEARS, a 3D printer specifically engineered for dental applications. For aesthetic and discreet alignment, they offer AsoAligner, a clear, slim, and visually unobtrusive mouthpiece-style orthodontic device. Complementing these offerings is ASO Digital, a dedicated service for 3D printing and modeling. Additionally, ASO International manufactures a broad spectrum of orthodontic appliances, such as study models, both IDB lingual and conventional lingual types, band-and-wire devices, resin-based options, functional appliances, retainers, and various other correctional tools. Their service portfolio is further enhanced by AILINE, which provides convenient teleconsultation capabilities.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +1.90% | +1.16% | -3.33% | +1.90% | -4.13% | +23.14% | +115.12% | +76.46% | +76.46% | +76.46% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Instruments & Supplies: +7.9%+7.1% Q1'26: +8.7% (vs Q1'25)
-
EPS growth Medical - Instruments & Supplies: +16.3%+12.9% Q1'26: +22.4% (vs Q1'25)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%+13.3% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Medical - Instruments & Supplies: +13.5%+17.5% ★ Q1'26: +18.3% (vs Q1'25)
-
ROIC Medical - Instruments & Supplies: +6.0%+48.5% ★ Q1'26: +42.7% (vs Q1'25)
-
Share dilution Medical - Instruments & Supplies: +0.1%+0.5% Q1'26: +0.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×0.00× ★ Q1'26: 0.00× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Jun 2025 actual |
Jun 2026 1 Rev. Ana. 1 EPS Ana. |
Jun 2027 1 Rev. Ana. 1 EPS Ana. |
Jun 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|
| Revenue |
3.80B
est: 3.84B (-1.1%)
|
4.10B
4.10B – 4.10B
+6.8% YoY
|
4.50B
4.50B – 4.50B
+9.8% YoY
|
4.90B
4.90B – 4.90B
+8.9% YoY
|
| EBITDA |
706.97M
est: 695.05M (+1.7%)
|
742.11M
742.11M – 742.11M
+6.8% YoY
|
814.51M
814.51M – 814.51M
+9.8% YoY
|
886.91M
886.91M – 886.91M
+8.9% YoY
|
| EBIT |
662.39M
est: 647.45M (+2.3%)
|
691.29M
691.29M – 691.29M
+6.8% YoY
|
758.73M
758.73M – 758.73M
+9.8% YoY
|
826.17M
826.17M – 826.17M
+8.9% YoY
|
| Net Income |
438.58M
est: 459.52M (-4.6%)
|
498.40M
498.40M – 498.40M
+8.5% YoY
|
569.17M
569.17M – 569.17M
+14.2% YoY
|
660.88M
660.88M – 660.88M
+16.1% YoY
|
| SGA |
1.05B
est: 1.10B (-5.2%)
|
1.18B
1.18B – 1.18B
+6.8% YoY
|
1.29B
1.29B – 1.29B
+9.8% YoY
|
1.41B
1.41B – 1.41B
+8.9% YoY
|
| EPS |
44.90
est: 46.10 (-2.6%)
|
50.00
50.00 – 50.00
+8.5% YoY
|
57.10
57.10 – 57.10
+14.2% YoY
|
66.30
66.30 – 66.30
+16.1% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-14 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-13 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-12 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-11 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-08 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-07 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-01 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-30 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-28 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-27 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-24 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-23 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-22 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-21 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-20 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-17 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-16 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Asano | General Manager of Business Administration Division. | — | — |
| Jun Uchiyama | GM & Director | — | male |
| Takumi Hirano | Executive Officer & Sales Manager | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 9340.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
